Phase I: Safety and Tolerance of Lactobactocillus reuteri in Adults

第一阶段:罗伊氏乳杆菌在成人中的安全性和耐受性

基本信息

项目摘要

DESCRIPTION (provided by applicant): A Phase 1 Study will be conducted in order to determine safety and tolerability of L. reuteri DSM 17938, 10^8 CFU daily, in treating healthy adults. It is required by the FDA that we conduct a Phase 1 study showing the safety and efficacy of L. reuteri (in sunflower oil) drops in adults before conducting our infant colic study. The study includes a single dose 5 x 10^8, 5 drops daily of L. reuteri; and we will determine the effects, if any, in subjects receiving recommended manufactured dose. This study will be conducted over a one year period with the first two months being the most critical. During the first two months, patients will attend 7 scheduled appointments and maintain bi-weekly diaries, serum chemistries, and 3 and 6-month follow-up visits. Adverse events will be recorded. We have received final IRB approval of this project on 4/24/2009 (#08-0266). Results of this study are expected to show safety and tolerability and will enable the FDA to approve studies of L. reuteri in infants with colic (and other illnesses). The long term goals are to elucidate mechanisms of intestinal disease in children ages (0 - 18 years) and identify viable treatments. Relevant to the NIH mission, this proposal is designed as a Phase I Study in Healthy Adults testing the efficacy and tolerability of L. reuteri. But in addition, we will determine effects of LR on baseline and stimulated levels of a cytokine panel in peripheral blood mononuclear cells (PBMC) after stimulation by PMA plus ionomycin; TLR2 and TLR4 expression in human PBMC; number of Treg cells in human PBMC; and fecal calprotectin assay. We also hope to conduct future research on probiotic therapeutic interventions in gastrointestinal diseases. Much more information is needed to characterize the complex gut microflora-immune system in association with gastrointestinal conditions in newborns such as colic. Public Health Relevance: Our studies would provide evidence for safety of probiotics, more specifically l. reuteri. Evidence could identify the early onset of gastrointestinal conditions, such as Irritable Bowel Syndrome. L. reuteri could possibly assist in the prevention of acute diarrhea and allergic disease. We will demonstrate if treatment of l. reuteri in healthy adults shows efficacy and tolerability. Also if physiologically, l. reuteri has an autoimmune effect on the human system, more specifically toll like receptors and cytokines identifying the specific strain as pro-inflammatory or anti-inflammatory. A mechanism could be identified for a particular probiotic and its effects on the gastrointestinal system.
描述(由申请人提供):将进行第一阶段研究,以确定罗伊氏乳杆菌 DSM 17938(每日 10^8 CFU)治疗健康成人的安全性和耐受性。 FDA 要求我们在进行婴儿绞痛研究之前先进行一期研究,证明罗伊氏乳杆菌(葵花籽油中)滴剂对成人的安全性和有效性。 该研究包括单剂量 5 x 10^8、每天 5 滴罗伊氏乳杆菌;我们将确定对接受推荐制造剂量的受试者的影响(如果有)。 这项研究将持续一年,其中前两个月最为关键。 在前两个月内,患者将参加 7 次预约,并保持每两周一次的日记、血清化学分析以及 3 个月和 6 个月的随访。 不良事件将被记录。 我们已于 2009 年 4 月 24 日收到该项目的最终 IRB 批准 (#08-0266)。 这项研究的结果预计将显示安全性和耐受性,并使 FDA 能够批准罗伊氏乳杆菌用于患有肠绞痛(和其他疾病)的婴儿的研究。 长期目标是阐明儿童(0 - 18 岁)肠道疾病的机制并确定可行的治疗方法。 与 NIH 使命相关,该提案被设计为健康成人的 I 期研究,测试罗伊氏乳杆菌的功效和耐受性。 但此外,我们将确定 LR 对 PMA 加离子霉素刺激后外周血单核细胞 (PBMC) 中细胞因子组的基线和刺激水平的影响;人PBMC中TLR2和TLR4的表达;人PBMC中Treg细胞的数量;和粪便钙卫蛋白测定。我们还希望未来能够开展益生菌治疗胃肠道疾病的研究。 需要更多的信息来描述复杂的肠道菌群-免疫系统与新生儿胃肠道疾病(如绞痛)的关系。 公共卫生相关性: 我们的研究将为益生菌的安全性提供证据,更具体地说是l。罗伊特里。 证据可以识别胃肠道疾病的早期发作,例如肠易激综合症。 罗伊氏乳杆菌可能有助于预防急性腹泻和过敏性疾病。 我们将演示 l 的治疗情况。罗伊氏菌在健康成人中显示出有效性和耐受性。另外,如果从生理上来说,l。罗伊氏菌对人体系统具有自身免疫作用,更具体地说是 Toll 样受体和细胞因子,可识别特定菌株的促炎性或抗炎性。可以确定特定益生菌及其对胃肠系统影响的机制。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JON Marc RHOADS其他文献

JON Marc RHOADS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JON Marc RHOADS', 18)}}的其他基金

Road to discovery for combination probiotic BB-12 with LGG in treating autism spectrum disorder
益生菌 BB-12 与 LGG 组合治疗自闭症谱系障碍的发现之路
  • 批准号:
    10657357
  • 财政年份:
    2018
  • 资助金额:
    $ 11.4万
  • 项目类别:
Road to discovery for combination probiotic BB-12 with LGG in treating autism spectrum disorder
益生菌 BB-12 与 LGG 组合治疗自闭症谱系障碍的发现之路
  • 批准号:
    9766942
  • 财政年份:
    2018
  • 资助金额:
    $ 11.4万
  • 项目类别:
Road to discovery for combination probiotic BB-12 with LGG in treating autism spectrum disorder
益生菌 BB-12 与 LGG 组合治疗自闭症谱系障碍的发现之路
  • 批准号:
    10439571
  • 财政年份:
    2018
  • 资助金额:
    $ 11.4万
  • 项目类别:
Road to discovery for combination probiotic BB-12 with LGG in treating autism spectrum disorder
益生菌 BB-12 与 LGG 组合治疗自闭症谱系障碍的发现之路
  • 批准号:
    9969235
  • 财政年份:
    2018
  • 资助金额:
    $ 11.4万
  • 项目类别:
Safety and Effect of L. reuteri on Biomarkers of Inflammation in Healthy Infants
罗伊氏乳杆菌的安全性及其对健康婴儿炎症生物标志物的影响
  • 批准号:
    8650793
  • 财政年份:
    2012
  • 资助金额:
    $ 11.4万
  • 项目类别:
Safety and Effect of L. reuteri on Biomarkers of Inflammation in Healthy Infants
罗伊氏乳杆菌的安全性及其对健康婴儿炎症生物标志物的影响
  • 批准号:
    8304030
  • 财政年份:
    2012
  • 资助金额:
    $ 11.4万
  • 项目类别:
Effect of Lactobactocillus Rhamnosus GG on Colic Symptoms and Breath Hydrogen
鼠李糖乳杆菌 GG 对绞痛症状和呼气氢的影响
  • 批准号:
    7314788
  • 财政年份:
    2008
  • 资助金额:
    $ 11.4万
  • 项目类别:
Phase I: Safety and Tolerance of Lactobactocillus reuteri in Adults
第一阶段:罗伊氏乳杆菌在成人中的安全性和耐受性
  • 批准号:
    7663878
  • 财政年份:
    2008
  • 资助金额:
    $ 11.4万
  • 项目类别:
Phase I: Safety and Tolerance of Lactobactocillus reuteri in Adults
第一阶段:罗伊氏乳杆菌在成人中的安全性和耐受性
  • 批准号:
    8259339
  • 财政年份:
    2008
  • 资助金额:
    $ 11.4万
  • 项目类别:
MECHANISMS OF INTESTINAL CELL MIGRATION
肠细胞迁移的机制
  • 批准号:
    6381820
  • 财政年份:
    2000
  • 资助金额:
    $ 11.4万
  • 项目类别:

相似海外基金

Un/kindness, shame & resistance: the care of inpatients in NHS adult acute mental health units and how it might be improved
Un/善良,羞耻
  • 批准号:
    2885806
  • 财政年份:
    2023
  • 资助金额:
    $ 11.4万
  • 项目类别:
    Studentship
Post-Acute Care Transitions for Older Adult Medicare Beneficiaries with Serious Mental Illness
患有严重精神疾病的老年医疗保险受益人的急性后护理过渡
  • 批准号:
    10772386
  • 财政年份:
    2023
  • 资助金额:
    $ 11.4万
  • 项目类别:
Paving The Way to a Canadian Standard of Care with CAR-T Cellular Therapy: Phase II Trial of CD19 CAR-T for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia (CLIC-01A)
通过 CAR-T 细胞疗法为加拿大护理标准铺平道路:CD19 CAR-T 治疗复发/难治性成人急性淋巴细胞白血病的 II 期试验 (CLIC-01A)
  • 批准号:
    474619
  • 财政年份:
    2022
  • 资助金额:
    $ 11.4万
  • 项目类别:
    Operating Grants
Investigating the impact acute inhalation of cannabis with a high content of delta-9-tetrahydrocannabinol has on myelination and microglia in adult and aged mice
研究急性吸入高含量 delta-9-四氢大麻酚的大麻对成年和老年小鼠髓鞘形成和小胶质细胞的影响
  • 批准号:
    485965
  • 财政年份:
    2022
  • 资助金额:
    $ 11.4万
  • 项目类别:
    Studentship Programs
Paving The Way to a Canadian Standard of Care with CAR-T Cellular Therapy: Phase II Trial of CD19 CAR-T for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia (CLIC-01A)
通过 CAR-T 细胞疗法为加拿大护理标准铺平道路:CD19 CAR-T 治疗复发/难治性成人急性淋巴细胞白血病的 II 期试验 (CLIC-01A)
  • 批准号:
    466358
  • 财政年份:
    2022
  • 资助金额:
    $ 11.4万
  • 项目类别:
    Operating Grants
Metabolomics for prediction of cisplatin mediated acute kidney injury: a Canadian multi-centre adult and pediatric study
预测顺铂介导的急性肾损伤的代谢组学:加拿大多中心成人和儿童研究
  • 批准号:
    402040
  • 财政年份:
    2019
  • 资助金额:
    $ 11.4万
  • 项目类别:
    Operating Grants
Study of pathogenic mechanism of age-dependent chromosome translocation in adult acute lymphoblastic leukemia
成人急性淋巴细胞白血病年龄依赖性染色体易位发病机制研究
  • 批准号:
    18K16103
  • 财政年份:
    2018
  • 资助金额:
    $ 11.4万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Causal effect of time-varying driving pressures on mortality in mechanically ventilated, adult patients with acute respiratory distress syndrome
时变驱动压力对机械通气成年急性呼吸窘迫综合征患者死亡率的因果影响
  • 批准号:
    377313
  • 财政年份:
    2017
  • 资助金额:
    $ 11.4万
  • 项目类别:
    Studentship Programs
Role of SETBP1 in adult Ph+ acute lymphoblastic leukemia
SETBP1 在成人 Ph 急性淋巴细胞白血病中的作用
  • 批准号:
    9315111
  • 财政年份:
    2016
  • 资助金额:
    $ 11.4万
  • 项目类别:
Acute Inhibition of Adult-born Granule Cells and its Effect on Antidepressant Act
成体颗粒细胞的急性抑制及其抗抑郁作用
  • 批准号:
    8734273
  • 财政年份:
    2013
  • 资助金额:
    $ 11.4万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了